AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01642849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high carbohydrate diet
Description: 12 subjects will be placed on a hig carbohydrate diet for 6 months
Study NCT01424163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Dose
Description: Treatment 3 (Part A)
Study NCT04041791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
Study NCT04041791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
Study NCT04041791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Description: Maintenance fluids administered for at least 24 hours.
Study NCT04041791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluid
Description: Maintenance fluids administered for at least 24 hours.
Study NCT04041791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasogastric feeds
Description: Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
Study NCT04041791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: Ampicillin is a penicillin-type antibiotic.
Study NCT01704105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old.
Study NCT04041791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin
Description: Ampicillin is a penicillin-type antibiotic.
Study NCT00206076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
Study NCT00206076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: mycophenolate mofetil monotherapy
Study NCT03981731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac coherence
Description: An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape.
Study NCT01832922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study NCT01832922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Study NCT01832922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT01832922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT00735176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Description: Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
Study NCT00735176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Description: Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
Study NCT02620137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multicentrum® (Pfizer, Spain) 3 months
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
Study NCT02620137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multicentrum® (Pfizer, Spain) 12 months
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
Study NCT03125408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HCV Assay
Description: Molecular diagnostic test to detect Hepatitus C
Study NCT01103713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus chloroquine
Description: Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
Study NCT03658954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice
Description: Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.
Study NCT03658954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice
Description: Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.
Study NCT03658954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will complete daily smartphone-based sleep and alcohol diaries for two weeks.
Study NCT03658954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Philips actiwatches and SCRAM ankle biosensors \& tailored coaching with a health coach
Study NCT02933658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02933658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Study NCT02933658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT01654419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Class II elastics and Sliding Jig
Description: Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
Study NCT01654419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II elastic alone
Description: Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
Study NCT01360138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical epidural steroid injection
Description: cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
Study NCT01731457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: adding appropriate dose of etanercept to the perfusion fluid
Study NCT02144844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insight-Plus Cognitive Behavioral Intervention
Description: Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
Study NCT03633760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 40mg single dose
Description: Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine
Study NCT03633760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine 20mg single-dose followed by multiple-dose
Description: Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.
Study NCT01653782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini yoga
Description: Guided training twice a week for six weeks. Self instructing cd for home practice
Study NCT01653782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self care advice
Description: Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book
Study NCT01653782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book
Study NCT00550056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Six session of Narrative Exposure Therapy
Study NCT00550056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Counselling
Description: Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
Study NCT02538861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT Imaging Test at Baptist hospital
Description: Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
Study NCT02538861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital
Description: The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
Study NCT00799162 — intervention group
Intervention type: OTHER
Intervention: Psychophysical testing, questionnaires, and genetics
Description: pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
Study NCT03073798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
Study NCT03073798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast
Description: 500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
Study NCT03073798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500 mcg of placebo is used
Study NCT03073798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mcg of placebo is used
Study NCT03119077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1161116
Description: Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
Study NCT03119077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
Study NCT03119077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
Study NCT03119077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
Study NCT01874535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 mg
Description: Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
Study NCT02353936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily
Study NCT02827045 — intervention group
Intervention type: DEVICE
Intervention: Vestibular test
Study NCT04568174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPSGG
Description: an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
Study NCT02538861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT Imaging Test at West Kendall Baptist Hospital
Description: Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
Study NCT04240353 — intervention group
Intervention type: OTHER
Intervention: COPD digital support service
Description: Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
Study NCT00245882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordination
Description: Care coordination with monthly follow-up by a diabetes nurse educator
Study NCT00245882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Telemedicine
Description: Active care management by a nurse practitioner using home telemedicine
Study NCT04568174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
Study NCT00793104 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placement of allograft CR Plug in primary injury site
Description: Core defect and implant allograft CR plug
Study NCT03890276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HMS EL&C training module
Description: No additional information
Study NCT03890276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMS EL&C training module
Description: No additional information
Study NCT03517319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9% 1.2 ml
Study NCT03890276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos used to supplement live trainer
Description: \[Cherrie to add\]
Study NCT03517319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U
Study NCT03517319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U
Study NCT02012972 — intervention group
Intervention type: BEHAVIORAL
Intervention: Referral for NCD care
Description: Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
Study NCT03517319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U
Study NCT00599586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
Study NCT03517319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
Study NCT00045162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles
Study NCT00045162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: 100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles
Study NCT00045162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: 60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles
Study NCT02032316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent
Description: Renal stent placed after uncomplicated uteroscopy
Study NCT00471094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT00471094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT00471094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT00471094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT01186458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
Study NCT01186458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
Study NCT01186458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
Study NCT03476226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Dysfunction Coping Strategy Teaching Sheet
Description: Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
Study NCT01991548 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
Study NCT01202435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 82.5 mg
Description: 82.5 mg controlled release tablet administered once daily for four days.
Study NCT01202435 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 25 mg
Description: 25 mg immediate release capsules administered three times daily for four days
Study NCT02452463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02452463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study NCT00599586 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
Study NCT00846612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: 1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle
Study NCT00846612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: 1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
Study NCT03176212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk fat globule membrane
Study NCT03176212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk fat globule membrane
Study NCT01984112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locked plate
Description: Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
Study NCT01984112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramedullary locked nail
Description: Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
Study NCT05537428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Intervention
Description: A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
Study NCT02202603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet
Study NCT02202603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: subcutaneous standard injection